FINWIRES · TerminalLIVE
FINWIRES

$DOCS

12 stories mentioning DOCS

Every FINWIRES story that references DOCS, newest first.

Sectors

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally higher.The iShares Biotechnology ETF (IBB) decreased 0.7%.In corporate news, Prestige Consumer Healthcare's (PBH) officials said Thursday that weak eye care sales and a difficult consumer backdrop drove disappointing fiscal Q4 results at the consumer healthcare products company. Its shares were down past 11%.Biogen (BIIB) shares fell nearly 7% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding AI opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note. Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating. Doximity shares dropped more than 23%.Aveanna Healthcare (AVAH) shares jumped past 8% after it reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.

$AVAH$BIIB$DOCS$PBH
Wire

Top Midday Decliners

Doximity (DOCS) reported overnight lower fiscal Q4 adjusted earnings and issued fiscal Q1 and full-year 2027 revenue guidance below analysts' estimates.Multiple analysts also downgraded their respective ratings on the company's stock.Shares sank 25% following a surge in intraday trading volume to over 17.9 million from a daily average of about 3.08 million.Live Ventures (LIVE) swung to a net loss in fiscal Q2 as sales slipped from a year ago.Shares slumped 25% as intraday trading volume advanced to more than 41,000 from a daily average of about 5,000.Aeluma (ALMU) reported Wednesday a swing to a fiscal Q3 loss and a year-over-year drop in revenue.Shares dropped 17%, with intraday trading volume at over 4.52 million versus a daily average of about 1.35 million.Price: $17.48, Change: $-5.91, Percent Change: -25.27%

$ALMU$DOCS$LIVE
Sectors

Sector Update: Healthcare Stocks Softer Thursday Afternoon

Healthcare stocks edged down Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) decreased 0.5%.In corporate news, Biogen (BIIB) shares fell nearly 6% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.Prestige Consumer Healthcare (PBH) reported weaker-than-expected Q4 results and issued 2026 guidance below consensus, with the shortfall driven primarily by supply constraints in Clear Eyes and broader execution pressures, Oppenheimer said in a note. Oppenheimer downgraded the stock to perform from outperform and removed its $65 price target. Prestige shares slumped past 8%.Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding AI opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note. Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating. Doximity shares dropped more than 24%.Aveanna Healthcare (AVAH) shares jumped 11% after it reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.

$AVAH$BIIB$DOCS$PBH
Wire

Doximity Growth Slowdown, Weak Outlook Raise Concerns, Morgan Stanley Says

Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding artificial intelligence opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note Thursday.The company reported fiscal Q4 revenue of $145 million, up 5% from a year earlier and slightly above Wall Street estimates. However, the company guided fiscal Q1 revenue below Wall Street estimates and forecast fiscal 2027 revenue growth of 4% at the midpoint, disappointing analysts who expected stronger trends in the healthcare digital advertising market, according to the note.The investment firm said the stock could remain in the "penalty box" in the near term, as it cited several "positives that will likely get overlooked," including a roughly 30% increase in active prescribers using Doximity's workflow tools to more than 800,000 users.The firm also cited early traction for the company's AI search product, which won deals with top pharmaceutical companies within weeks of launch.Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating.Shares of Doximity were falling more than 26% in late morning trading Thursday.Price: $17.24, Change: $-6.15, Percent Change: -26.29%

$DOCS
Commodities

Exchange-Traded Funds, Equity Futures Advance Pre-Bell Thursday Amid US-China Meeting

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.2% higher in Thursday's premarket activity amid a two-day meeting between the US and China.US stock futures were also higher, with S&P 500 Index futures up 0.3%, Dow Jones Industrial Average futures advancing 0.7%, and Nasdaq futures gaining 0.2% before the start of regular trading.US initial jobless claims rose to a level of 211,000 in the week ended May 9 from a downwardly revised 199,000 level in the previous week, compared with expectations for a smaller increase to 205,000 in a survey of analysts compiled by Bloomberg.US import prices rose by 1.9% in April, above the 1% increase expected in a survey compiled by Bloomberg as of 7:35 am ET and faster than a 0.9% gain in March.US retail sales rose by 0.5% in April, as expected in a survey compiled by Bloomberg as of 7:35 am ET and following the previous month's 1.6% gain.Business inventory data for March is due to be released at 10 am ET, followed by weekly natural gas stocks at 10:30 am ET.Federal Reserve Kansas City President Jeffrey Schmid, Cleveland President Beth Hammack, New York President John Williams, and Governor Michael Barr are slated to speak on Thursday.In premarket action, bitcoin was down by 10%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.2% lower, Ether ETF (EETH) advanced 0.2%, and Bitcoin & Ether Market Cap Weight ETF (BETH) retreated by 0.01%.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.2%. The Vanguard Health Care Index Fund (VHT), the iShares US Healthcare ETF (IYH), and the iShares Biotechnology ETF (IBB) were flat.Doximity (DOCS) stock was down more than 10% premarket after the company overnight reported a steeper-than-expected drop in fiscal Q4 adjusted earnings and sales guidance for the next financial year lagged market expectations.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) gained by 0.4%, and the iShares US Technology ETF (IYW) was 0.5% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 0.7%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 0.3%, while the iShares Semiconductor ETF (SOXX) fell by 0.1%.Cisco Systems (CSCO) shares were up more than 15% in premarket activity after the company reported forecast-beating fiscal Q3 results and said it plans to lay off about 4,000 employees, representing around 5% of its workforce.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.1%, and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) gained 0.3%. The iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increased by 0.3%. The VanEck Retail ETF (RTH) retreated by 0.01%, while the State Street SPDR S&P Retail ETF (XRT) was 0.3% higher.Yeti (YETI) shares were up more than 10% pre-bell after the company reported better-than-expected fiscal Q1 adjusted net income and net sales.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated by 0.2%, while the Vanguard Industrials Index Fund (VIS) gained 0.04% and the iShares US Industrials ETF (IYJ) was inactive.Copa (CPA) stock was up more than 3% before the opening bell after the company reported higher Q1 earnings and operating revenue.EnergyThe iShares US Energy ETF (IYE) was down 0.3%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.02%.Consolidated Edison (ED) stock was down more than 2% before the opening bell. Goldman Sachs raised its price target on the company to $105 from $103 and maintained its sell rating.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.4%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.9%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.8% lower.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 0.1% to $100.95 per barrel on the New York Mercantile Exchange. Natural gas was down 0.7% to $2.84 per 1 million British Thermal Units. The United States Oil Fund (USO) decreased by 0.7%, while the United States Natural Gas Fund (UNG) was flat.Gold futures for May retreated by 0.1% to $4,700.30 an ounce on the Comex. Silver futures fell by 2.3% to $87.30 an ounce. SPDR Gold Shares (GLD) was 0.2% higher, and the iShares Silver Trust (SLV) declined by 0.8%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$CPA$CSCO$DOCS$ED$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$PMR$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD$YETI
Research

KeyBanc Downgrades Doximity to Sector Weight From Overweight

Doximity (DOCS) has an average rating of overweight and mean price target of $28.11, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$DOCS
Research

Jefferies Downgrades Doximity to Hold From Buy, Adjusts Price Target to $19 From $51

Doximity (DOCS) has an average rating of overweight and mean price target of $28.11, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$DOCS
Research

Wells Fargo Downgrades Doximity to Equal Weight From Overweight, Cuts Price Target to $18 From $32

Doximity (DOCS) has an average rating of overweight and mean price target of $28.11, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$DOCS
Research

Baird Downgrades Doximity to Neutral From Outperform, Adjusts Price Target to $18 From $40

Doximity (DOCS) has an average rating of overweight and mean price target of $28.11, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$DOCS
Research

BTIG Downgrades Doximity to Neutral From Buy

Doximity (DOCS) has an average rating of overweight and mean price target of $28.11, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$DOCS
Wire

Update: Doximity Fiscal Q4 Adjusted Earnings Miss Estimate; FY27 Sales Guidance Lags; Shares Plunge Premarket

(Updates with the stock move in the headline and the first paragraph.)Doximity (DOCS) shares were down over 21% at the time of writing premarket Thursday after the company overnight reported a steeper-than-expected drop in fiscal Q4 adjusted earnings and sales guidance for the next financial year lagged market expectations.The company reported fiscal Q4 adjusted earnings late Wednesday of $0.26 per diluted share, down from $0.38 a year earlier.Analysts polled by FactSet expected $0.28.Revenue for the three months ended March 31 was $145.4 million, up from $138.3 million a year earlier.Analysts surveyed by FactSet expected $144 million.For Q1, the company expects revenue of $151 million to $152 million.Analysts expect $153.8 million.For fiscal 2027, the company expects revenue of $664 million to $676 million.Analysts expect $697.4 million.Price: $18.42, Change: $-4.97, Percent Change: -21.25%

$DOCS
Research

Truist Downgrades Doximity to Hold From Buy, Cuts Price Target to $29 From $37

Doximity (DOCS) has an average rating of overweight and mean price target of $37.43, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$DOCS